secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001493152-24-031477
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix Q2 2024 net loss widens to $5.8M; cash runway extended to Q4 2026
---------------------------------------------------------------------------

- Net loss widened to $5.8M ($1.59/sh) from $3.8M ($1.04) a year ago; revenue fell to $1.6M from $1.8M.
- Cash and equivalents $12.4M plus $1.4M restricted cash released; projected cash runway into Q4 2026 after MannKind transactions.
- Recorded $2.6M loss on disposal group for assets transferred to MannKind in connection with iSPERSE technology validation.
- Halted Phase 2b enrollment for PUR1900 with Cipla; wind down by Q3 2024; no further development funding, 2% royalty on future ex-US sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224031477/0001493152-24-031477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224031477/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer